Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines

Nishtman Dizeyi, Petter Hedlund, Anders Bjartell, Martina Tinzl, Kristin Austild-Taskén, Per Anders Abrahamsson

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: This study was conducted to examine the effects of 5-HT on extracellular signal-regulated kinase 1/2 (Erk1/2) and Akt pathways in prostate cancer (PC) cells. Methods: PC cell lines PC-3, Du145, and LNCaP stimulated with 5-HT in the presence of MEK or PI3K inhibitors and 5-HT receptor subtype 1A antagonist were analyzed by Western blotting and immunofluorescence. The proliferation assay BrdU and Boyden chamber were used to determine proliferation and migration, respectively. Results: 5-HT dose-dependently induced rapid activation of Erk1/2 in PC-3 and Du145 cells, whereas in LNCaP cells, Erk1/2 phosphorylation was slow and sustained for up to 18 h. Similarly, 5-HT induced phosphorylation of Akt within 1 hour of stimulation, however, Akt phosphorylation was more pronounced in Du145 cells compared with PC-3 or LNCaP cells. The action of 5-HT was inhibited to varying degrees by inhibitors of MAPK and PI3K as well as by a 5-HT receptor subtype 1A antagonist. In addition to proliferation, 5-HT induced migration of PC-3 and Du145 cells, which were alleviated by the aforementioned inhibitors. The effects of 5-HT on LNCaP cells appeared to be related to neuroendocrine-phenotype acquisition and chromogranin A and neuron specific enolase expression. Conclusions: This study addresses the role of 5-HT in Erk1/2 and Akt activation in PC cells. The data presented here identify 5-HT receptors as a novel target in castration-resistant PC. Furthermore, our observations are in line with previous studies, which point towards neuroendocrine factors facilitating progression and migration of prostatic cancer cells in an androgen-deficient environment. Nonetheless, additional studies are warranted to corroborate the role of 5-HTR antagonists as a potential target for anticancer therapy.

Original languageEnglish
Pages (from-to)436-445
Number of pages10
JournalUrologic Oncology: Seminars and Original Investigations
Volume29
Issue number4
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Phosphatidylinositol 3-Kinases
Prostatic Neoplasms
Serotonin
Phosphotransferases
Cell Line
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Receptor, Serotonin, 5-HT1A
Phosphorylation
Chromogranin A
Phosphopyruvate Hydratase
Serotonin Receptors
Castration
Mitogen-Activated Protein Kinase Kinases
Bromodeoxyuridine
Androgens
Fluorescent Antibody Technique
Western Blotting
Phenotype

Keywords

  • 5-HT
  • 5-HTR antagonist
  • MAPK/Erk1/2
  • PI3K/Akt
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. / Dizeyi, Nishtman; Hedlund, Petter; Bjartell, Anders; Tinzl, Martina; Austild-Taskén, Kristin; Abrahamsson, Per Anders.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 29, No. 4, 07.2011, p. 436-445.

Research output: Contribution to journalArticle

Dizeyi, Nishtman ; Hedlund, Petter ; Bjartell, Anders ; Tinzl, Martina ; Austild-Taskén, Kristin ; Abrahamsson, Per Anders. / Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. In: Urologic Oncology: Seminars and Original Investigations. 2011 ; Vol. 29, No. 4. pp. 436-445.
@article{f6e1cc48ef02411783e0f2c8dfaf13ed,
title = "Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines",
abstract = "Purpose: This study was conducted to examine the effects of 5-HT on extracellular signal-regulated kinase 1/2 (Erk1/2) and Akt pathways in prostate cancer (PC) cells. Methods: PC cell lines PC-3, Du145, and LNCaP stimulated with 5-HT in the presence of MEK or PI3K inhibitors and 5-HT receptor subtype 1A antagonist were analyzed by Western blotting and immunofluorescence. The proliferation assay BrdU and Boyden chamber were used to determine proliferation and migration, respectively. Results: 5-HT dose-dependently induced rapid activation of Erk1/2 in PC-3 and Du145 cells, whereas in LNCaP cells, Erk1/2 phosphorylation was slow and sustained for up to 18 h. Similarly, 5-HT induced phosphorylation of Akt within 1 hour of stimulation, however, Akt phosphorylation was more pronounced in Du145 cells compared with PC-3 or LNCaP cells. The action of 5-HT was inhibited to varying degrees by inhibitors of MAPK and PI3K as well as by a 5-HT receptor subtype 1A antagonist. In addition to proliferation, 5-HT induced migration of PC-3 and Du145 cells, which were alleviated by the aforementioned inhibitors. The effects of 5-HT on LNCaP cells appeared to be related to neuroendocrine-phenotype acquisition and chromogranin A and neuron specific enolase expression. Conclusions: This study addresses the role of 5-HT in Erk1/2 and Akt activation in PC cells. The data presented here identify 5-HT receptors as a novel target in castration-resistant PC. Furthermore, our observations are in line with previous studies, which point towards neuroendocrine factors facilitating progression and migration of prostatic cancer cells in an androgen-deficient environment. Nonetheless, additional studies are warranted to corroborate the role of 5-HTR antagonists as a potential target for anticancer therapy.",
keywords = "5-HT, 5-HTR antagonist, MAPK/Erk1/2, PI3K/Akt, Prostate cancer",
author = "Nishtman Dizeyi and Petter Hedlund and Anders Bjartell and Martina Tinzl and Kristin Austild-Task{\'e}n and Abrahamsson, {Per Anders}",
year = "2011",
month = "7",
doi = "10.1016/j.urolonc.2009.09.013",
language = "English",
volume = "29",
pages = "436--445",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines

AU - Dizeyi, Nishtman

AU - Hedlund, Petter

AU - Bjartell, Anders

AU - Tinzl, Martina

AU - Austild-Taskén, Kristin

AU - Abrahamsson, Per Anders

PY - 2011/7

Y1 - 2011/7

N2 - Purpose: This study was conducted to examine the effects of 5-HT on extracellular signal-regulated kinase 1/2 (Erk1/2) and Akt pathways in prostate cancer (PC) cells. Methods: PC cell lines PC-3, Du145, and LNCaP stimulated with 5-HT in the presence of MEK or PI3K inhibitors and 5-HT receptor subtype 1A antagonist were analyzed by Western blotting and immunofluorescence. The proliferation assay BrdU and Boyden chamber were used to determine proliferation and migration, respectively. Results: 5-HT dose-dependently induced rapid activation of Erk1/2 in PC-3 and Du145 cells, whereas in LNCaP cells, Erk1/2 phosphorylation was slow and sustained for up to 18 h. Similarly, 5-HT induced phosphorylation of Akt within 1 hour of stimulation, however, Akt phosphorylation was more pronounced in Du145 cells compared with PC-3 or LNCaP cells. The action of 5-HT was inhibited to varying degrees by inhibitors of MAPK and PI3K as well as by a 5-HT receptor subtype 1A antagonist. In addition to proliferation, 5-HT induced migration of PC-3 and Du145 cells, which were alleviated by the aforementioned inhibitors. The effects of 5-HT on LNCaP cells appeared to be related to neuroendocrine-phenotype acquisition and chromogranin A and neuron specific enolase expression. Conclusions: This study addresses the role of 5-HT in Erk1/2 and Akt activation in PC cells. The data presented here identify 5-HT receptors as a novel target in castration-resistant PC. Furthermore, our observations are in line with previous studies, which point towards neuroendocrine factors facilitating progression and migration of prostatic cancer cells in an androgen-deficient environment. Nonetheless, additional studies are warranted to corroborate the role of 5-HTR antagonists as a potential target for anticancer therapy.

AB - Purpose: This study was conducted to examine the effects of 5-HT on extracellular signal-regulated kinase 1/2 (Erk1/2) and Akt pathways in prostate cancer (PC) cells. Methods: PC cell lines PC-3, Du145, and LNCaP stimulated with 5-HT in the presence of MEK or PI3K inhibitors and 5-HT receptor subtype 1A antagonist were analyzed by Western blotting and immunofluorescence. The proliferation assay BrdU and Boyden chamber were used to determine proliferation and migration, respectively. Results: 5-HT dose-dependently induced rapid activation of Erk1/2 in PC-3 and Du145 cells, whereas in LNCaP cells, Erk1/2 phosphorylation was slow and sustained for up to 18 h. Similarly, 5-HT induced phosphorylation of Akt within 1 hour of stimulation, however, Akt phosphorylation was more pronounced in Du145 cells compared with PC-3 or LNCaP cells. The action of 5-HT was inhibited to varying degrees by inhibitors of MAPK and PI3K as well as by a 5-HT receptor subtype 1A antagonist. In addition to proliferation, 5-HT induced migration of PC-3 and Du145 cells, which were alleviated by the aforementioned inhibitors. The effects of 5-HT on LNCaP cells appeared to be related to neuroendocrine-phenotype acquisition and chromogranin A and neuron specific enolase expression. Conclusions: This study addresses the role of 5-HT in Erk1/2 and Akt activation in PC cells. The data presented here identify 5-HT receptors as a novel target in castration-resistant PC. Furthermore, our observations are in line with previous studies, which point towards neuroendocrine factors facilitating progression and migration of prostatic cancer cells in an androgen-deficient environment. Nonetheless, additional studies are warranted to corroborate the role of 5-HTR antagonists as a potential target for anticancer therapy.

KW - 5-HT

KW - 5-HTR antagonist

KW - MAPK/Erk1/2

KW - PI3K/Akt

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=79959897334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959897334&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.09.013

DO - 10.1016/j.urolonc.2009.09.013

M3 - Article

C2 - 19926313

AN - SCOPUS:79959897334

VL - 29

SP - 436

EP - 445

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -